Birth Tissue Implant Coating Prevents Adverse Responses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical implants and devices often cause adverse responses such as thrombogenesis, adhesion, pain, inflammation, infection, necrosis, and rejection due to biologic responses, leading to complications that require additional surgical procedures and patient discomfort.
Innovation Solution
Applying a birth tissue material coating composition, including components like placental tissue, umbilical cord blood, and amniotic membrane, to the external surface of implants to reduce or prevent adverse responses, which can include thrombogenesis, adhesion, pain, inflammation, infection, necrosis, and rejection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional biodegradable polymer coatings are applied to implants, then pharmaceutical agents can be delivered locally at the site of medical intervention, but adverse responses such as thrombogenesis, adhesion, inflammation, and rejection still occur requiring secondary surgical procedures
Solution Approach 1:
The patent introduces a gelatin coating derived from placental tissue as an intermediary layer between the implant surface and the patient's biological system. This gelatin coating acts as a mediator that reduces direct adverse interactions between the implant and host tissues, specifically preventing thrombogenesis, adhesion, and inflammation without requiring secondary surgical interventions.
Solution Approach 2:
The invention combines gelatin (a natural biopolymer) with placental tissue-derived components to create a composite coating material. This composite structure integrates the biocompatibility of gelatin with the bioactive properties of placental tissues, providing enhanced prevention of adverse responses including thrombogenesis and rejection while maintaining structural integrity on the implant surface.
2Strength
If implants are made from synthetic materials (metal, ceramic, polymer), then structural strength and durability are improved, but biologic responses such as metal sensitivity, thrombogenesis, and rejection occur
Solution Approach 1:
The patent applies the gelatin coating specifically to the external surface of the implant where it directly contacts biological tissues. This localized treatment maintains the bulk structural properties of the synthetic implant material while modifying only the surface properties to be biocompatible, preventing thrombogenesis and adhesion at the implant-tissue interface without compromising overall structural strength.
Solution Approach 2:
The gelatin coating serves as an intermediary layer between the synthetic implant material and the patient's biological system. This intermediate layer prevents direct harmful interactions between synthetic materials and host tissues, reducing metal sensitivity, thrombogenesis, and rejection responses while allowing the synthetic implant to maintain its structural function.
3Reliability
If grafts are obtained from natural sources (autograft, allograft, xenograft), then biocompatibility is improved, but complications such as graft rejection, infection, and inflammation still occur
Solution Approach 1:
The gelatin coating is designed as a temporary, biodegradable layer that provides protective functions during the critical initial period after implantation. As the coating naturally degrades over time, it has already performed its function of preventing thrombogenesis, adhesion, and infection during the most vulnerable phase, after which it is safely absorbed by the body without requiring removal.
Data Source
AI summary
Methods of reducing or preventing an adverse response to an implanted or inserted material in a patient are provided. The methods include the step of treating at least a portion of an external surface of the implanted or inserted material with an effective amount of a birth tissue material coating corn position.